Savient Pharmaceuticals, Inc. Sustainability Profile
Savient Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 2001, the company has made significant strides in developing innovative therapies for rare diseases, particularly in the field of metabolic disorders. Savient is best known for its flagship product, Krystexxa, which offers a unique treatment option for chronic gout, setting it apart in a competitive market. With a focus on research and development, Savient has established a strong market position, catering to patients with unmet medical needs. The company operates primarily in North America, with a commitment to advancing healthcare solutions that improve patient outcomes. Through its dedication to innovation and quality, Savient Pharmaceuticals continues to make a meaningful impact in the biopharmaceutical landscape.
DitchCarbon Score
How does Savient Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Savient Pharmaceuticals, Inc.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Savient Pharmaceuticals, Inc.'s reported carbon emissions
In 2023, Savient Pharmaceuticals, Inc. reported carbon emissions primarily from various operational activities, with notable figures including approximately 91,250 kg CO2e from solar photovoltaic (PV) systems and about 13,000 kg CO2e from recycled plastic usage. Additionally, the company recorded significant emissions from business travel, amounting to approximately 4,626,000 kg CO2e in 2021. Savient Pharmaceuticals has not disclosed specific targets for emissions reduction or climate commitments, nor does it appear to have cascaded any reduction targets from a parent or related organisation. The absence of defined Scope 1, 2, or 3 emissions data suggests that the company may still be in the early stages of formalising its climate strategy. Overall, while Savient Pharmaceuticals has made some strides in measuring its carbon footprint, further commitments and reduction initiatives are necessary to align with industry standards for climate action.
How Carbon Intensive is Savient Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Savient Pharmaceuticals, Inc.'s Location?
Savient Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Savient Pharmaceuticals, Inc. has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
